In Vivo and Ex Vivo Gene Electrotransfer in Ophthalmological Disorders
The aim of this document is to present an overview of gene electrotransfer in ophthalmological disorders. In order to ensure an adequate variety of the assessed studies, several electronic databases were considered and studies published between January 1998 and December 2021 were analysed. Three inv...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/10/8/1889 |
| _version_ | 1827618076504358912 |
|---|---|
| author | Roberta Fusco Giacomo Perazzolo Gallo Elio Di Bernardo Valeria D’Alessio Mattia Ronchetti Matteo Cadossi Ruggero Cadossi |
| author_facet | Roberta Fusco Giacomo Perazzolo Gallo Elio Di Bernardo Valeria D’Alessio Mattia Ronchetti Matteo Cadossi Ruggero Cadossi |
| author_sort | Roberta Fusco |
| collection | DOAJ |
| description | The aim of this document is to present an overview of gene electrotransfer in ophthalmological disorders. In order to ensure an adequate variety of the assessed studies, several electronic databases were considered and studies published between January 1998 and December 2021 were analysed. Three investigators carried out data extraction and analysis, focusing on both technical (i.e., electrical protocol, type of electrode, plasmid) and medical (i.e., type of study, threated disease) aspects and highlighting the main differences in terms of results obtained. Moreover, the IGEA experience in the project “Transposon-based, targeted ex vivo gene therapy to treat age-related macular degeneration” (TargetAMD) was reported in the results section. No clinical trial was found on international literature and on ClinicalTrials.gov. Twelve preclinical studies were found including in vivo and ex-vivo applications. The studied showed that electrotransfer could be very efficient for plasmid DNA transfection. Many attempts such as modification of the electric field, buffers and electrodes have been made and the optimization of electric field setting seems to be very important. Using this technique, gene replacement can be designed in cases of retinal inheritance or corneal disease and a wide range of human eye diseases could, in the future, benefitfrom these gene therapy technologies. |
| first_indexed | 2024-03-09T10:00:31Z |
| format | Article |
| id | doaj.art-816b4ffe25a64e9bba59b943c0a8e55b |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-09T10:00:31Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-816b4ffe25a64e9bba59b943c0a8e55b2023-12-01T23:27:40ZengMDPI AGBiomedicines2227-90592022-08-01108188910.3390/biomedicines10081889In Vivo and Ex Vivo Gene Electrotransfer in Ophthalmological DisordersRoberta Fusco0Giacomo Perazzolo Gallo1Elio Di Bernardo2Valeria D’Alessio3Mattia Ronchetti4Matteo Cadossi5Ruggero Cadossi6Oncology Medical and Research & Development Division, IGEA SpA, 41012 Carpi, ItalyOncology Medical and Research & Development Division, IGEA SpA, 41012 Carpi, ItalyOncology Medical and Research & Development Division, IGEA SpA, 41012 Carpi, ItalyOncology Medical and Research & Development Division, IGEA SpA, 41012 Carpi, ItalyRegulatory Affairs, BVI—Optikon 2000, 00138 Rome, ItalyOncology Medical and Research & Development Division, IGEA SpA, 41012 Carpi, ItalyOncology Medical and Research & Development Division, IGEA SpA, 41012 Carpi, ItalyThe aim of this document is to present an overview of gene electrotransfer in ophthalmological disorders. In order to ensure an adequate variety of the assessed studies, several electronic databases were considered and studies published between January 1998 and December 2021 were analysed. Three investigators carried out data extraction and analysis, focusing on both technical (i.e., electrical protocol, type of electrode, plasmid) and medical (i.e., type of study, threated disease) aspects and highlighting the main differences in terms of results obtained. Moreover, the IGEA experience in the project “Transposon-based, targeted ex vivo gene therapy to treat age-related macular degeneration” (TargetAMD) was reported in the results section. No clinical trial was found on international literature and on ClinicalTrials.gov. Twelve preclinical studies were found including in vivo and ex-vivo applications. The studied showed that electrotransfer could be very efficient for plasmid DNA transfection. Many attempts such as modification of the electric field, buffers and electrodes have been made and the optimization of electric field setting seems to be very important. Using this technique, gene replacement can be designed in cases of retinal inheritance or corneal disease and a wide range of human eye diseases could, in the future, benefitfrom these gene therapy technologies.https://www.mdpi.com/2227-9059/10/8/1889gene electrotransferophthalmological disordersin vivoex-vivo |
| spellingShingle | Roberta Fusco Giacomo Perazzolo Gallo Elio Di Bernardo Valeria D’Alessio Mattia Ronchetti Matteo Cadossi Ruggero Cadossi In Vivo and Ex Vivo Gene Electrotransfer in Ophthalmological Disorders Biomedicines gene electrotransfer ophthalmological disorders in vivo ex-vivo |
| title | In Vivo and Ex Vivo Gene Electrotransfer in Ophthalmological Disorders |
| title_full | In Vivo and Ex Vivo Gene Electrotransfer in Ophthalmological Disorders |
| title_fullStr | In Vivo and Ex Vivo Gene Electrotransfer in Ophthalmological Disorders |
| title_full_unstemmed | In Vivo and Ex Vivo Gene Electrotransfer in Ophthalmological Disorders |
| title_short | In Vivo and Ex Vivo Gene Electrotransfer in Ophthalmological Disorders |
| title_sort | in vivo and ex vivo gene electrotransfer in ophthalmological disorders |
| topic | gene electrotransfer ophthalmological disorders in vivo ex-vivo |
| url | https://www.mdpi.com/2227-9059/10/8/1889 |
| work_keys_str_mv | AT robertafusco invivoandexvivogeneelectrotransferinophthalmologicaldisorders AT giacomoperazzologallo invivoandexvivogeneelectrotransferinophthalmologicaldisorders AT eliodibernardo invivoandexvivogeneelectrotransferinophthalmologicaldisorders AT valeriadalessio invivoandexvivogeneelectrotransferinophthalmologicaldisorders AT mattiaronchetti invivoandexvivogeneelectrotransferinophthalmologicaldisorders AT matteocadossi invivoandexvivogeneelectrotransferinophthalmologicaldisorders AT ruggerocadossi invivoandexvivogeneelectrotransferinophthalmologicaldisorders |